Targeting the stress response kinase GCN2 to restore immunity in the tumor microenvironment. SITC 2018 on November 9, 2018. View poster (PDF)

CCR4 Antagonists Inhibit Treg Trafficking into the Tumor Microenvironment. ACS Medicinal Chemistry Letters on September 10, 2018. View paper

Discovery and Optimization of Potent and Selective Inhibitors of USP7 to Enhance Anti-Tumor Immunity and Target Tumor Growth. AACR 2018 on April 16, 2018. View poster (PDF)

EBV-Associated Tumors Increase Regulatory T Cell Recruitment via CCR4 Ligand Expression and are a Promising Indication for Treatment with Small Molecule CCR4 Inhibitors. AACR 2018 on April 17, 2018.
View poster (PDF)

Potent and Selective CCR4 Antagonists Inhibit Regulatory T Cell Recruitment, Increase Effector T Cell Numbers, and Potentiate Anti-Tumor Responses in Mice. SITC 2017 on November 11, 2017. View poster (PDF)

Patient Selection Strategies and Pharmacodynamic Assays for CCR4 Antagonists. SITC 2017 on November 10, 2017. View poster (PDF)

Potent and selective C-C chemokine receptor (CCR4) antagonists potentiate anti-tumor immune responses by inhibiting regulatory T cells (Treg). AACR on April 2, 2017. View poster (PDF)